search
Back to results

The Effects of Using Yupingfeng Powder With Variation for the Treatment of Allergic Rhinitis

Primary Purpose

Allergic Rhinitis

Status
Recruiting
Phase
Phase 2
Locations
Hong Kong
Study Type
Interventional
Intervention
Yupingfeng Powder granules
Placebo
Sponsored by
Prof. Lin Zhixiu
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Allergic Rhinitis focused on measuring Allergic Rhinitis, Yupingfeng Powder variation

Eligibility Criteria

5 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age d above 5;
  • Subjects with deficiency of lung and spleen Qi;
  • At least 2 or more allergic symptoms rhinorrhea , sneezing , nasal obstruction and nasal itching for a cumulative period greater than 1 hour per day. These symptoms may be accompanied by itchy and red eyes and tears;
  • Positive srum IgE test;
  • Voluntary written consent.

Exclusion Criteria:

  • Known chronic disease such as asthma, rhinosinusitis, nasal polyposis;
  • Known severe medical conditions, such as cardiovascular, liver or renal dysfunction, diabetes mellitus, cancers, cerebrovascular diseases, blood system diseases;
  • Concomitant steroid, nonsteroidal anti inflammatory drugs (NSAIDs), anticoagulant, and immunotherapy within past month;
  • Impaired hematological profile and liver / renal function;
  • Known alcohol and / or drug abuse;
  • Known allergic history to any Chinese herbal medicines;
  • Subjects who are pregnant or lactating.

Sites / Locations

  • The Chinese University of Hong KongRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Active Arm

Placebo Arm

Arm Description

14.55g of Yupingfeng Powder granules twice daily for 8 weeks

14.55g of placebo granules twice daily for 8 weeks

Outcomes

Primary Outcome Measures

The change in the Total Nasal Symptom Score (TNSS)
The TNSS evaluates 4 nasal symptoms ( rhinorrhea, sneezing, nasal obstruction and nasal itching) which will be self assessed by subjects using a four point scale, with low scores indicating less severe nasal symptoms

Secondary Outcome Measures

The change in the Total Nasal Symptom Score (TNSS)
The TNSS evaluates 4 nasal symptoms ( rhinorrhea, sneezing, nasal obstruction and nasal itching) which will be self assessed by subjects using a four point scale, with low scores indicating less severe nasal symptoms
The changes in frequency of AR episodes and their severity on visual analog scale (VAS)
The VAS ranges from 0 (nasal symptom free) to 10 (nasal symptom extremely bothersome) to assess the severity of nasal symptom disturbance
The changes in quality of life by using The changes in the Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ)
The lower the score the higher the quality of life
The changes in quality of life by using The changes in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
The lower the score the higher the quality of life
The changes in the serum levels of specific IgE
The serum levels of cytokines and IgE will be tested. The higher the value, the more severity of the symptoms.
The changes in the serum levels of cytokines (IL-10 and IL-17)
Serum responses will correlate with the nasal symptoms scores.
The changes in the gut microbiota composition in stools
The composition of gut microbiota will be tested to observe the influence of Chinese. Gut microbiome compositions will be characterised by shotgun sequencing total DNA extracted from stools.
Adverse events related to study treatment
All adverse events that are related to the study treatment will be captured for analysis.

Full Information

First Posted
June 10, 2021
Last Updated
June 21, 2022
Sponsor
Prof. Lin Zhixiu
search

1. Study Identification

Unique Protocol Identification Number
NCT04976023
Brief Title
The Effects of Using Yupingfeng Powder With Variation for the Treatment of Allergic Rhinitis
Official Title
The Effects of Using Yupingfeng Powder With Variation for the Treatment of Allergic Rhinitis(AR):a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 12, 2022 (Actual)
Primary Completion Date
August 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Prof. Lin Zhixiu

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Allergic rhinitis (AR) is an IgE mediated chronic inflammatory disease of the upper airways characterized by symptoms of sneezing, rhinorrhea, nasal itching, and nasal obstruction . However, not only this disease is difficult to cure, but also its relapse rate is high, therefore exerting a certain impact on their daily life, work and study. Nowadays, the main treatment for allergic rhinitis is the use of western medicine, such as steroids and antihistamines. However, many clinical studies have found that the curative effect of western medicine is often not ideal. Allergic rhinitis belongs to the category of "Rhinitis" in Chinese medicine. From the perspective of Chinese medicine, this disease is resulted from the deficiency of Qi and Yang Qi in the lungs, spleen and kidneys. Therefore, according to Chinese medicine theory, tonifying lung and spleen qi is the treatment principle for AR patients. Among different Chinese herbal formulae for AR, Yupingfeng san is commonly used for allergic diseases and in AR patients, due to its warm nature and able to improve the functions of the lungs and spleen. Yupingfeng san can improve symptoms and quality of life, as well as decrease the levels of interleukin and IgE in AR patients. This study will use Yupingfeng Powder with variation to evaluate its effectiveness and safety in treating AR. Hence, this study would be able to provide evidence on the efficacy and safety of Yupingfeng Powder with variation for AR.
Detailed Description
Rhinitis is broadly defined as inflammation of the nasal mucosa. It is a common disorder that affects up to 40% of the population. Allergic rhinitis (AR) is the most common type of chronic rhinitis, affecting 10-20% of the population, and evidence suggests that the prevalence of the disorder is increasing. AR is a very common clinical disease that can occur at any age. Severe allergic rhinitis has been associated with significant impairments in quality of life, sleep and work performance. Allergic rhinitis is a complex immune and inflammatory disease. Its pathogenesis has not yet been fully known, and there is no clear way to cure. It is an IgE-mediated chronic inflammatory disease of the upper airways characterized by symptoms of sneezing, rhinorrhea, nasal itching, and nasal obstruction, and cytokines such as IL-17 and IL-10 play an essential role in mediating allergic inflammation. Nowadays, the main treatment for allergic rhinitis is the use of western medicine, such as steroids and antihistamines. However, many clinical studies have found that the curative effect of western medicine is often not ideal. Chinese herbal medicine (CHM) is a well tolerated choice for AR patients seeking complementary and alternative therapies to reduce AR symptoms. In recent years, studies have found that Yupingfeng Powder not only has few side effects (feeling of abdominal distension or increased in acne are reported), it can al so increase anti allergic ability and improve body's resistance, thus showing the advantages of oral Chinese medicine in the treatment of AR. Accordingly, CHM may influence the gastrointestinal system, including the intestinal mucosa and gut microbiota, the latter of which is essential for health and closely linked to diseases. A few systematic reviews and studies indicate that certain probiotics are beneficial for patients with AR. In this study, fifty-eight eligible subjects will be recruited from Paediatric out-patient clinic and community, and randomly assigned to receive orally Yupingfeng Powder with variation or placebo twice a day for 8 weeks, with follow-up for another 8 weeks after stopping the treatment to observe the duration of efficacy and to explore the mechanism of Yupingfeng Powder in treating AR with respect to the immune response and gut microbiota.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Allergic Rhinitis
Keywords
Allergic Rhinitis, Yupingfeng Powder variation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
58 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Active Arm
Arm Type
Active Comparator
Arm Description
14.55g of Yupingfeng Powder granules twice daily for 8 weeks
Arm Title
Placebo Arm
Arm Type
Placebo Comparator
Arm Description
14.55g of placebo granules twice daily for 8 weeks
Intervention Type
Drug
Intervention Name(s)
Yupingfeng Powder granules
Other Intervention Name(s)
Yupingfeng Powder with variation
Intervention Description
14.5 5 g twice daily for 8 weeks
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
Placebo granules
Intervention Description
14.5 5 g twice daily for 8 weeks
Primary Outcome Measure Information:
Title
The change in the Total Nasal Symptom Score (TNSS)
Description
The TNSS evaluates 4 nasal symptoms ( rhinorrhea, sneezing, nasal obstruction and nasal itching) which will be self assessed by subjects using a four point scale, with low scores indicating less severe nasal symptoms
Time Frame
Week 8
Secondary Outcome Measure Information:
Title
The change in the Total Nasal Symptom Score (TNSS)
Description
The TNSS evaluates 4 nasal symptoms ( rhinorrhea, sneezing, nasal obstruction and nasal itching) which will be self assessed by subjects using a four point scale, with low scores indicating less severe nasal symptoms
Time Frame
week 4, week 12 and week 16
Title
The changes in frequency of AR episodes and their severity on visual analog scale (VAS)
Description
The VAS ranges from 0 (nasal symptom free) to 10 (nasal symptom extremely bothersome) to assess the severity of nasal symptom disturbance
Time Frame
week 4, week 8, week 12 and week 16
Title
The changes in quality of life by using The changes in the Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ)
Description
The lower the score the higher the quality of life
Time Frame
week 4, week 8, week 12 and week 16
Title
The changes in quality of life by using The changes in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
Description
The lower the score the higher the quality of life
Time Frame
week 4, week 8, week 12 and week 16
Title
The changes in the serum levels of specific IgE
Description
The serum levels of cytokines and IgE will be tested. The higher the value, the more severity of the symptoms.
Time Frame
week 8 and week 12
Title
The changes in the serum levels of cytokines (IL-10 and IL-17)
Description
Serum responses will correlate with the nasal symptoms scores.
Time Frame
week 8 and week 12
Title
The changes in the gut microbiota composition in stools
Description
The composition of gut microbiota will be tested to observe the influence of Chinese. Gut microbiome compositions will be characterised by shotgun sequencing total DNA extracted from stools.
Time Frame
week 8
Title
Adverse events related to study treatment
Description
All adverse events that are related to the study treatment will be captured for analysis.
Time Frame
During study for 16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age d above 5; Subjects with deficiency of lung and spleen Qi; At least 2 or more allergic symptoms rhinorrhea , sneezing , nasal obstruction and nasal itching for a cumulative period greater than 1 hour per day. These symptoms may be accompanied by itchy and red eyes and tears; Positive srum IgE test; Voluntary written consent. Exclusion Criteria: Known chronic disease such as asthma, rhinosinusitis, nasal polyposis; Known severe medical conditions, such as cardiovascular, liver or renal dysfunction, diabetes mellitus, cancers, cerebrovascular diseases, blood system diseases; Concomitant steroid, nonsteroidal anti inflammatory drugs (NSAIDs), anticoagulant, and immunotherapy within past month; Impaired hematological profile and liver / renal function; Known alcohol and / or drug abuse; Known allergic history to any Chinese herbal medicines; Subjects who are pregnant or lactating.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhixiu Lin, PhD
Phone
35053476
Email
linzx@cuhk.edu.hk
First Name & Middle Initial & Last Name or Official Title & Degree
Jessica Y.L. Ching, MPH
Phone
35053524
Email
jessicaching@cuhk.edu.hk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhixiu Lin, PhD
Organizational Affiliation
Hong Kong Institute of Integrative Medicine, The Chinese University of Hong Kong
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Chinese University of Hong Kong
City
Shatin
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhi-xiu Lin, PhD
Email
linzx@cuhk.edu.hk

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Effects of Using Yupingfeng Powder With Variation for the Treatment of Allergic Rhinitis

We'll reach out to this number within 24 hrs